GlassScriptPhysician profile
Brian J Olzinski
NPI 1760476758
$5,747.18
in general payments reported to CMS, 2019-2025
26 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $154 · 2021: $626 · 2022: $1,128 · 2023: $1,123 · 2024: $1,016 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,242 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.36 |
| Education | $197.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $994.70 | 2019-2025 | Eysuvis, Precision7, Total30 |
| Mallinckrodt Hospital Products INC. | $973.88 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $673.74 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $449.26 | 2022-2025 | Miebo, Xiidra, Infuse |
| Abbvie INC. | $377.40 | 2022-2025 | |
| Oyster Point Pharma, INC. | $243.55 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $233.62 | 2019-2021 | |
| Amgen INC. | $199.25 | 2024-2025 | Tepezza |
| Glaukos Corporation | $193.79 | 2024-2025 | Idose, Istent Inject W, Idosetr |
| Coopervision INC. | $191.73 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Novartis Pharmaceuticals Corporation | $142.12 | 2019-2022 | |
| Allergan, INC. | $139.52 | 2019-2021 | |
| Rxsight INC | $130.59 | 2022 | |
| Horizon Therapeutics Plc | $128.41 | 2023 | Tepezza |
| Shire North American Group INC | $124.78 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $104.91 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $96.62 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $83.80 | 2020-2025 | |
| Dompe US, INC. | $64.08 | 2021-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $61.06 | 2019-2024 | |
| Harrow Eye, LLC | $46.66 | 2024-2025 | Vevye, Iheezo |
| Quidel Corporation | $24.37 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $18.58 | 2024 | Dextenza |
| Katena Products, INC. (Dba Corza Medical) | $17.90 | 2019 | |
| Spark Therapeutics, INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Olzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.